Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


PP-UNP-USA-5796

Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.

 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426


​​​​​​​PP-UNP-USA-5796

Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796

Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading

PP-UNP-USA-5796

Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVO

About ABRYSVO

Efficacy ProfileImmunobridgingSafety ProfilePatient ProfilesDosing, Storage, & ReconstitutionReal-World EvidenceOrder ABRYSVO

Order ABRYSVO

Order ABRYSVORefer ABRYSVOAccess & Support

Access & Support

Health Plan CoverageRequest a RepVaccine LocatorMaterialsVideos
Prescribing InformationIndicationsPatient SiteMaternal
ABRYSVO® is approved to prevent RSV-LRTD in adults aged 18-59 at increased risk1ABRYSVO demonstrated noninferior immunogenicity in adults aged 18-59 (MONeT study), compared to adults aged 60 and older (RENOIR study)1Full study designPhase 3 study of adults 18-59: MONeT1
  • Multicenter, randomized, double-blind, placebo-controlled study to assess the safety and immunogenicity of ABRYSVO
  • Adults aged 18-59 (median age, 49 years) who were considered to be at increased risk of RSV-LRTD due to certain chronic medical conditions
  • Enrolled patients had the following chronic conditions: cardiovascular (excluding isolated hypertension), hematologic, hepatic, metabolic (including diabetes
mellitus and hyper/hypothyroidism), neurologic, pulmonary (including asthma), or renal disorders
  • ~675 patients were randomized to receive ABRYSVO (n=453) or placebo (n=225)
  • The vaccine and placebo groups were also similar with regard to the prevalence of underlying medical conditions, which included 52% with ≥1 chronic pulmonary condition, 43% with diabetes, 31% with ≥1 other disease (liver, renal, neurologic, hematologic, or other metabolic disease), and 8% with ≥1 cardiovascular condition
  • Participants were followed for safety for up to 6 months
Noninferiority criteria1
  • Effectiveness was assessed by comparison of the RSV-neutralizing GMTs and seroresponse rates of the evaluable immunogenicity population in MONeT who received ABRYSVO (n=437) to those of a subgroup of individuals aged 60+ from select sites in the U.S. and Japan in RENOIR (n=410)
  • Noninferiority was demonstrated for the ratio of neutralizing GMTs for RSV-A and RSV-B (MONeT/RENOIR subgroup; lower bounds of the 2-sided 95% CIs >0.667), 
and the percentage difference in neutralizing titer seroresponse rates for RSV-A 
and RSV-B (MONeT minus RENOIR; lower bound of the 2-sided 95% CI was >-10%)
CI=confidence interval; GMT=geometric mean titers; LRTD=lower respiratory tract disease; 
RSV=respiratory syncytial virus.Reference:ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; June 2025.ReferencesNoninferiority was met if the lower bound of the 2-sided CI of adjusted GMR (MONeT/RENOIR) was >0.667 (1.5-fold noninferiority criterion) for both RSV-A and RSV-B. Neutralizing geometric mean titers for RSV-A were 41,097 in MONeT and 26,225 in RENOIR; for RSV-B they were 37,416 in MONeT and 24,680 in RENOIR.1Analysis of covariance model was used per protocol with sex and baseline titer (in logarithm scale) adjusted.1Noninferiority was met if the lower bound of the 2-sided CI for the percentage difference (MONeT minus RENOIR) was >-10% for both RSV-A and RSV-B. The neutralizing titer seroresponse rates for RSV-A were 93% in MONeT and 88% in RENOIR; for RSV-B they were 93% in MONeT and 85% in RENOIR.1Seroresponse is defined as achieving a ≥4-fold rise from baseline if the baseline measurement is above the LLOQ. If the baseline measurement is below the LLOQ, a post-vaccination assay result ≥4 × LLOQ is considered to be a seroresponse.1CI=confidence interval; GMR=geometric mean ratio; GMT=geometric mean titer; LLOQ=lower limit of quantitation; LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; SRR=seroresponse rate.About ABRYSVO
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View Resources

Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading View ResourcesLoading
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View ResourcesLoading
References:ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; June 2025.Davis M, Towner W, DeHaan E, et al; for the MONeT Study Team. Bivalent RSVpreF vaccine in adults 18 to <60 years old with high-risk conditions. Clin Infect Dis. 2025;80(4):911-920.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-2410
IndicationsABRYSVO is a vaccine indicated for:
 
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions
were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions
were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367